ALG-055009

DRUG4 trials

Sponsors

Aligos Therapeutics

Conditions

Healthy Volunteer StudyHealthy VolunteersMASHMetabolic Dysfunction-Associated SteatohepatitisNASHNASH - Nonalcoholic SteatohepatitisNonalcoholic Steatohepatitis

Phase 1

A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

CompletedNCT05090111

Aligos TherapeuticsNASH - Nonalcoholic Steatohepatitis

Start: 2021-12-01End: 2023-06-16Updated: 2023-09-25

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

CompletedNCT06191991

Aligos TherapeuticsHealthy Volunteers

Start: 2023-11-03End: 2023-12-04Updated: 2025-02-17

A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

CompletedNCT06959888

Aligos TherapeuticsHealthy Volunteer Study

Start: 2025-03-25End: 2025-05-16Updated: 2025-07-09

Phase 2

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)

CompletedNCT06342947

Aligos TherapeuticsMASH, Metabolic Dysfunction-Associated Steatohepatitis, NASH +1

Start: 2024-04-01End: 2024-09-09Updated: 2025-02-17

Related Papers

ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.

2026-08-26